On Monday, Recursion Pharmaceuticals Inc (NASDAQ: RXRX) opened lower -12.25% from the last session, before settling in for the closing price of $7.51. Price fluctuations for RXRX have ranged from $5.60 to $14.12 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 112.62% over the past five years. Company’s average yearly earnings per share was noted 18.24% at the time writing. With a float of $297.00 million, this company’s outstanding shares have now reached $389.55 million.
In terms of profitability, gross margin is 10.66%, operating margin of -814.58%, and the pretax margin is -790.4%.
Recursion Pharmaceuticals Inc (RXRX) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Recursion Pharmaceuticals Inc is 23.99%, while institutional ownership is 61.89%. The most recent insider transaction that took place on Feb 06 ’25, was worth 162,400. In this transaction Chief Executive Officer of this company sold 20,000 shares at a rate of $8.12, taking the stock ownership to the 1,273,156 shares. Before that another transaction happened on Feb 05 ’25, when Company’s Chief Executive Officer sold 20,000 for $7.68, making the entire transaction worth $153,600. This insider now owns 1,273,156 shares in total.
Recursion Pharmaceuticals Inc (RXRX) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.5 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 18.24% per share during the next fiscal year.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Trading Performance Indicators
Check out the current performance indicators for Recursion Pharmaceuticals Inc (RXRX). In the past quarter, the stock posted a quick ratio of 3.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 43.76.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.66, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach -1.24 in one year’s time.
Technical Analysis of Recursion Pharmaceuticals Inc (RXRX)
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) saw its 5-day average volume 26.94 million, a positive change from its year-to-date volume of 26.1 million. As of the previous 9 days, the stock’s Stochastic %D was 5.48%. Additionally, its Average True Range was 1.01.
During the past 100 days, Recursion Pharmaceuticals Inc’s (RXRX) raw stochastic average was set at 14.64%, which indicates a significant increase from 0.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 135.93% in the past 14 days, which was higher than the 98.58% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.59, while its 200-day Moving Average is $7.45. Nevertheless, the first resistance level for the watch stands at $7.46 in the near term. At $8.34, the stock is likely to face the second major resistance level. The third major resistance level sits at $8.78. If the price goes on to break the first support level at $6.14, it is likely to go to the next support level at $5.70. The third support level lies at $4.82 if the price breaches the second support level.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Key Stats
There are currently 390,722K shares outstanding in the company with a market cap of 2.58 billion. Presently, the company’s annual sales total 44,580 K according to its annual income of -328,070 K. Last quarter, the company’s sales amounted to 26,080 K and its income totaled -95,840 K.
